National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Thyroid Cancer Treatment (PDQ®)     
Last Modified: 09/23/2009
Health Professional Version
Changes to This Summary (09/23/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information 1

Updated statistics 2 with estimated new cases and deaths for 2009 (cited American Cancer Society as reference 1).

Cellular Classification 3

Added Mills et al. as reference 3 4.

Stage IV Papillary and Follicular Thyroid Cancer 5

Added text 6 to state that oral inhibitors of vascular endothelial growth-factor receptors are under clinical evaluation (cited Sherman et al. as reference 5 and level of evidence 2Dii).

Recurrent Thyroid Cancer 7

Added text 8 about a phase II study of sorafenib in advanced thyroid cancer (cited Gupta-Abramson et al. as reference 10 and level of evidence 3iiDiii).


Table of Links

1http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/1.c
dr#Section_1
2http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/243
.cdr#Section_243
3http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/6.c
dr#Section_6
4http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/10.
cdr#Section_10
5http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/113
.cdr#Section_113
6http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/171
.cdr#Section_171
7http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/146
.cdr#Section_146
8http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/280
.cdr#Section_280